Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Karen Lynch

Neurology North Chatham, MA Medical Doctor

NPI 1184855314 CMS profile 966626

390 Orleans Rd, North Chatham, MA 02650

Open in the dashboard

General payments

$118,567

256 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Karen Lynch of North Chatham, MA is reported in the CMS Open Payments database as having received $118,567 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $59 1
2023 General $11,831 16
2022 General $26,312 96
2021 General $41,745 50
2020 General $20,204 47
2019 General $18,417 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Lynch
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Karen Lynch were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Karen Lynch Neurology median Middle half National median
2019 $18,417 $474 $118–$2,177 $163
2020 $20,204 $367 $82–$2,309 $114
2021 $41,745 $438 $104–$2,547 $132
2022 $26,312 $442 $103–$2,388 $149
2023 $11,831 $464 $119–$2,312 $160
2024 $59 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Allergan Inc. $63,007 85 payments
  2. AbbVie, Inc. $52,779 87 payments
  3. Natus Medical Incorporated $525 1 payment
  4. Biohaven Pharmaceutical Holding Company Ltd. $434 10 payments
  5. Biohaven Pharmaceuticals, Inc. $250 5 payments
  6. Lilly USA, LLC $243 14 payments
  7. Genzyme Corporation $193 5 payments
  8. Amgen Inc. $150 4 payments
  9. Novartis Pharmaceuticals Corporation $102 5 payments
  10. Lundbeck LLC $100 3 payments
  11. Other $783 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $104,076 64 payments
  2. Travel and Lodging $7,211 29 payments
  3. Food and Beverage $4,909 156 payments
  4. Consulting Fee $1,800 4 payments
  5. Honoraria $525 1 payment
  6. Education $46 2 payments
Products named General payments · program years 2019–2024
  1. UBRELVY Neuroscience $45,717 53 payments
  2. BOTOX Neuroscience $36,165 42 payments
  3. BOTOX Neuroscience $17,947 23 payments
  4. UBRELVY Neuroscience $15,497 30 payments
  5. QULIPTA $9,478 15 payments
  6. NURTEC ODT $684 15 payments
  7. EMGALITY $243 14 payments
  8. BOTOX Hyperhydrosis $214 12 payments
  9. AIMOVIG $208 7 payments
  10. REYVOW $150 8 payments
  11. Other $1,153 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Neurology: 833

Drug cost

$193

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Phenytoin Sodium Extended Generic 12 $193

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$7,841

Medicare's payments for the services billed

Medicare patients

32

Average age 76

Services billed

453

17 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 38%
Ischemic heart disease 34%
Depression 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART
  • ARGENX US, INC. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record